Global Ophthalmic Drugs Contract Manufacturing Market Trends Report, 2020-2030

News provided by

Feb 18, 2020, 16:30 ET

DUBLIN, Feb. 18, 2020 /PRNewswire/ -- The "Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Current estimates indicate that the total economic burden related to vision loss is expected to reach approximately USD 384 billion by 2030, in the US alone

Ophthalmic Drugs Contract Manufacturing Market, 2020-2030 features an extensive study of the contract services market for ophthalmic products and solutions. It is worth mentioning that the study primarily focuses on small molecule active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), including ophthalmic drops, emulsions, gels, injections, lotions, ointments, suspensions, and tablets / capsules. It features in-depth analyses, highlighting the capabilities of a diverse set of CMOs and CDMOs.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as growth of the overall ophthalmic drugs market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030.

In order to provide a detailed future outlook, projections have been segmented on the basis of:

[A] type of product (APIs and FDFs),
[B] type of FDF manufactured (solids, semi-solids, and liquids / suspensions),
[C] type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, blister packing, and other forms),
[D] scale of manufacturing (preclinical, clinical, and commercial),
[E] company size (small sized, mid-sized, and large-sized companies),
[F] key disease indications (age-related macular degeneration, glaucoma, uveitis, dry eye, and other disease segments), and
[G] key geographical regions, covering North America (the US, Canada and Mexico), Europe (the UK, Germany, France, Spain, Italy and rest of Europe), and Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific).

The rise in incidence and prevalence of chronic eye disorders has prompted the medical research community to actively develop a variety of ophthalmic drugs / therapies. The current ophthalmic diseases treatment landscape is characterized by a number of blockbuster therapies, namely ALPHAGAN, COSOPT, LUMIGAN, PAZEO, RESTASIS, TRAVATAN Z, and XALATAN, and a robust pipeline of over 400 candidate drugs in various stages of clinical development, designed for the treatment of approximately 1,000 chronic eye disorders.

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic drug development and production operations to contract service providers.

Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are known to offer significant benefits, which include reduction in capital investment, access to larger production capacities, reductions in time-to-market and also guarantee a significant degree of commercial risk mitigation. Since 2000, more than 75 new ophthalmology focused CMOs have been established.

Amidst the tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry. This has caused many service providers to actively expand their respective service portfolios, either through strategic acquisitions or facility / capability expansions. Over time, many CMOs / CDMOs claim to have developed end-to-end service capabilities, ranging from drug development (including preliminary R&D, preclinical studies and clinical trials), to regulatory filings, and commercial scale production.

To account for the uncertainties associated with the growth of the ophthalmic drugs contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Amongst other elements, the report includes:

A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters, such as year of establishment, company size, geographical location, scale of operation (preclinical, pilot, clinical, and commercial), type of product (APIs and FDFs), type of FDF manufactured (solids, semi-solids, liquids, suspensions, and injectables), type of primary packaging (ampoules/vials, glass / plastic bottles, ointment tubes, sachets/pouches, blister packing, and other forms), type of service(s) offered (pre-formulation, drug formulation, method validation, process development, analytical testing, stability studies, technology transfer, scale-up, fill/finish, and regulatory support), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.
A company competitiveness analysis, highlighting prominent ophthalmic drug contract manufacturers based on supplier strength (which was calculated considering the size of employee base of a company and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities, and number of regulatory accreditations/certifications).
Elaborate profiles of key players based in North America, Europe and Asia-Pacific that offer a diverse range of capabilities for the development, manufacturing and packaging of ophthalmic drug products. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.
A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products, highlighting prevalent trends across parameters, such as current trial status, trial registration year, enrolled patient population and trial location, phase of development, study design, leading industry and non-industry players (in terms of number of trials undertaken / conducted), study focus, and key disease indications (in terms of number of trials undertaken / conducted).
An informed estimate of the annual commercial demand for ophthalmic APIs and drug FDFs (in million litres), taking into account the top 30 small molecule-based ophthalmic drugs; the analysis takes into consideration the target patient population, dosing frequency and dose strength of the aforementioned products. The annual clinical demand for ophthalmic drug products was also estimated, taking into account ongoing and planned clinical trials.
A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized, and large-sized CMOs) in the market, based on data gathered via secondary and primary research. It also provides the likely distribution of the global ophthalmic product-related manufacturing capacity available across different types of companies (small-sized, mid-sized, and large-sized), scales of operation (preclinical, clinical and commercial), types of FDFs manufactured (ampoules / vials, glass / plastic bottles, and ointment tubes), and key geographical regions (North America, Europe, and Asia-Pacific).
A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to ophthalmic drug developers.
A discussion on the emerging trends and potential market drivers, such as the growing ophthalmic drugs / therapies pipeline, rise in outsourcing activity for sterile manufacturing operations, adoption of innovative technologies and increasing opportunities in the Asia-Pacific region, which are likely to impact the evolution of the market in the coming years.
A detailed list of over 55 ophthalmic medical device contract manufacturers, along with information on year of establishment, company size, geographical location, key application area(s) (diagnostics, drug delivery, therapeutics, and others), type of manufacturing service(s) offered (design, component manufacturing, assembly, prototype development, sterilization, quality assurance, and packaging), type of additional service(s) offered (consultancy, documentation, inspection/testing, labelling, logistics, project management, regulatory support, repair, warehouse/storage, and others), scale of operation (pilot and commercial), device class-related expertise (class I, class II and class III), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.

Key Topics Covered

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Introduction to Ophthalmology
3.2.1. Anatomy of the Human Eye
3.2.2. Chronic Eye Conditions and Associated Economic Burden
3.3. Common Ophthalmic Drug Dosage Forms
3.3.1. Types of Oral Drug Formulations
3.3.1.1. Tablets
3.3.1.2. Capsules
3.3.1.3. Eye Supplements
3.3.2. Types of Semi-solid Formulations
3.3.2.1. Ointments
3.5.2.2. Gels
3.5.2.3. Emulsions
3.3.3. Types of Liquid Drug Formulations
3.3.3.1. Solutions
3.3.3.2. Suspensions
3.5.3.1. Sterile Injectables
3.3.4. Intraocular Inserts
3.4. Common Primary Packaging Formats for Ophthalmic Drugs
3.5. Overview of Contract Manufacturing
3.6. Outsourcing in the Ophthalmology Industry
3.6.1. Need for Outsourcing
3.6.2. Commonly Outsourced Operations
3.6.3. Guidelines for Selecting a Contract Manufacturing Organization (CMO) Partner
3.6.4. Advantages of Outsourcing Manufacturing Operations
3.6.5. Challenges Associated with Ophthalmic Drugs Contract Manufacturing
3.6.6. Growth Drivers and Roadblocks to Ophthalmic Drugs Contract Manufacturing
3.6.7. Recent Developments and Upcoming Trends

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Ophthalmic Drug Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Geographical Location
4.2.5. Analysis by Location of Manufacturing Facilities
4.2.6. Analysis by Type of Product
4.2.7. Analysis by Type of FDF Manufactured
4.2.8. Analysis by Type of Primary Packaging
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Regulatory Accreditations / Certifications

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Methodology
5.3. Competitiveness Analysis: Ophthalmic API Contract Manufacturers
5.3.1. Ophthalmic API Contract Manufacturers in North America
5.3.2. Ophthalmic API Contract Manufacturers in Europe
5.3.3. Ophthalmic API Contract Manufacturers in Asia-Pacific
5.4. Competitiveness Analysis: Ophthalmic Drug FDF Contract Manufacturers
5.4.1. Ophthalmic Drug FDF Contract Manufacturers in North America
5.4.2. Ophthalmic Drug FDF Contract Manufacturers in Europe
5.4.3. Ophthalmic Drug FDF Contract Manufacturers in Asia-Pacific

6. OPHTHALMIC DRUGS COUNTERACT MANUFACTURING IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. Akorn
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Service Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. Catalent
6.4. Cayman Chemical
6.5. Pillar5 Pharma
6.6. Sterling Pharmaceutical Services

7. OPHTHALMIC DRUGS COUNTERACT MANUFACTURING IN EUROPE: COMPANY PROFILES
7.1. Chapter Overview
7.2. FARMIGEA
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Lomapharm
7.4. Medichem
7.5. Recipharm
7.6. Salvat

8. OPHTHALMIC DRUGS COUNTERACT MANUFACTURING IN ASIA-PACIFIC: COMPANY PROFILES
8.1. Chapter Overview
8.2. Akums
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. Bal Pharma
8.4. Entod Pharmaceuticals
8.5. Glenmark Pharmaceuticals
8.6. Indiana Ophthalmics
8.7. Sunways India

9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Ophthalmic Drug Trial Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Geographical Analysis by Number of Clinical Trials
9.3.3. Geographical Analysis by Enrolled Patient Population
9.3.4. Analysis by Phase of Development
9.3.5. Analysis by Trial Recruitment Status
9.3.6. Analysis by Type of Sponsor / Collaborator
9.3.7. Most Active Players in Terms of Number of Registered Trials
9.3.8. Analysis by Type of Intervention
9.3.9. Analysis by Trial Focus
9.3.10. Analysis by Target Indication
9.3.11. Benchmark Analysis of Active Industry Players

10. CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Ophthalmic API Contract Manufacturers: Global Production Capacity (by Volume)
10.3.1. Analysis by Geography
10.3.2. Analysis by Scale of Operation
10.3.3. Analysis by Company Size
10.4. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity
10.4.1. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity (by Volume)
10.4.2. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity (by Number of Units)

11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Global Commercial Demand for Ophthalmic Drugs Contract Manufacturing
11.3.1. Commercial Demand for Ophthalmic API Contract Manufacturing
11.3.2. Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing
11.4. Global Clinical Demand for Ophthalmic Drugs Contract Manufacturing
11.4.1. Clinical Demand for Ophthalmic API Contract Manufacturing
11.4.2. Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing
11.5. Demand and Supply Analysis

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Overall Ophthalmic Drugs Contract Manufacturing Market, 2020-2030
12.4. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Product
12.5. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Target Disease Indication
12.6. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
12.7. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Size of Manufacturers
12.8. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Geographical Regions

13. CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE MOLECULE OPHTHALMIC DRUGS / THERAPIES
13.1. Chapter Overview
13.2. Small Molecule Drugs and Biologics
13.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
13.2.2. Comparison of Key Specifications
13.2.3. Comparison of Manufacturing Processes
13.2.4. Comparison of Key Manufacturing-related Challenges

14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Comparison of SWOT Factors

15. SURVEY ANALYSIS
15.1. Chapter Overview
15.2. Overview of Respondents
15.2.1. Seniority Level of Respondents
15.3. Survey Insights
15.3.1. Type of Product
15.3.2. Type of Primary Packaging
15.3.3. Scale of Operation
15.3.4. Manufacturing Capacity
15.3.5. Location of Manufacturing Facilities
15.3.6. Regulatory Accreditations / Certifications of Manufacturing Facilities
15.3.7. Extent of Outsourcing
15.3.8. Current Market Opportunity

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Selvok Pharmaceutical
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Rahul Gupta, Chief Executive Officer
16.3. Caplin Point Laboratories
16.4. Phytex Australia
16.5. Gland Pharma

17. FUTURE GROWTH OPPORTUNITIES
17.1. Chapter Overview
17.2. Integration / Adoption of New and Innovative Technologies
17.3. Capability and Expertise Expansions by CMOs
17.4. Offshoring Outsourcing Activities
17.5. Growing Investments in Existing Infrastructure
17.6. Evolving Client / Sponsor and CMO / CDMO Relationships
17.7. Business Acquisition and Consolidation Activity
17.8. Challenges Faced by Both Sponsors and Service Providers
17.8.1. Concerns Related to Single Use Systems
17.8.2. Concerns Related to Capacity Fluctuations

A-Z List of Companies Mentioned

A. S. Joshi & Company
Aarti Industries
Abbott Medical Optics
AccuMED
Actiza Pharmaceutical
Admac Formulations
Aerie Pharmaceuticals
AGC Biologics
Aishwarya Lifescience
Akorn
Akums
Alcon
Alembic Pharmaceuticals
Allergan
Amanta Healthcare
Ambica Pharma Sales
AMETEK Engineered Medical Components
Amman Pharmaceutical Industries
AMRI
ANI Pharmaceuticals
Apex Pharmaceuticals
Apicore US
Arvincare
Ashford Pharmaceutical Laboratories
Aspen Pharmacare
Assiut University
Astellas Pharma
Aster Pharma
AstraZeneca
Atrion Medical
Aurobindo Pharma
Avalign Technologies
Axa Parenterals
Bachem
BAL Pharma
Bausch & Lomb
Bayer
Baylor College of Medicine
Beijing Second Pharmaceutical
Bennet Pharmaceuticals
BePharBel
Beximco Pharmaceuticals
Binex
Biocon
Bioglan
Biomol
Biotech Vision Care
Boehringer Ingelheim
Bolivac Pharmaceutical
Bonarum Pharma
Brassica Pharma
Bristol-Myers Squibb
C&J Industries
Cadence
Cadila Pharmaceuticals
Cairo University
Cambrex
Caplin Point Laboratories
Capsugel
Captab Biotec
Carclo
Catalent
Cayman Chemical
CCM Pharmaceuticals
Centaur Pharmaceuticals
Center for Drug Evaluation and Research
Century Pharmaceuticals
Ceutical Labs
Chang Gung Memorial Hospital
Charit University
ChemCon
Chemigran
Chifeng Arker Pharmaceutical Technology
Chirogate International
Chongqing Huapont Pharmaceutical
Chromo Laboratories India
Ciron Drugs
CiVentiChem
Coastline International
COC Farmaceutici
Columbia University
Combino Pharm
Concord Drugs
Consort Medical
CooperVision
CoreRx
CTX Lifesciences
Daicel
Deepcare Health
Delorbis
Delpharm
Denator
Dermopartners
Deva Holding
DeviceLab
Dhruv Life Sciences
DM Pharma
Doctor Pack
Domp
Donatelle
Dr. Reddy's Laboratories
Duke University
Eden Healthcare
Edol Laboratory
EL Laboratories
Eminent Healthcare
Emory University
Enaltec Labs
Entod Pharmaceuticals
Eskayef Pharmaceuticals
Eurofins
Euro-Med Laboratories
EVCO Plastics
Evergreen Research
Evolet Healthcare
Excella
Excelvision
Exela Pharma Science
EXODRUG
Fabbrica Italiana Sintetici
FAMAR
Fantabulous Pharma
Fareva
Farmak
Farmastur 2010
FARMIGEA
FDC
Federal University of So Paulo
Fermion
Finecure Pharmaceuticals
FineTech Pharmaceuticals
Finnsusp
Flagship Biotech International
Flamma Group
Fleming Laboratories
Flexan
Forefront Medical Technology
Freudenberg Medical
FSUE Moscow Endocrine Plant
Galentic Pharma
Gedeon Richter
Genentech
Gerresheimer
Gland Pharma
Glaukos
GlaxoSmithKline
Glenmark Pharmaceuticals
Glochem Industries
Golden Drugs
Grevis Pharmaceuticals
Groupe SYNERLAB
Grupo Farmasierra
GTIMD
Guilin Pharmaceutical
Handok
Hangzhou Panyu Chemical
Hanuchem Laboratories
Harmac Medical Products
Health Biotech
Healthcare Pharmaceuticals
Healthy Life Pharma
Hemofarm
Hetero Drugs
Higgs Healthcare
Hi-Tech Pharmacal
Hospices Civils de Lyon
Hovione
Hritik Chemicals
Hubei Biocause Pharmaceutical
Icahn School of Medicine at Mount Sinai
IIFA Healthcare
Indena
Indiana Ophthalmics
Indoco Remedies
Ind-Swift
Instru-med
Intas Pharmaceuticals
Inteprod
Interquim
i-Pharmaceuticals
I-Tek Medical Technologies
ITL Group
IVERIC bio
J B Chemicals & Pharmaceuticals
Jabil
Jaeb Center for Health Research
Jawa pharmaceuticals
JGL
Jips Pharmaceuticals
Johns Hopkins University
Johnson & Johnson Vision Care
JSC Tatchempharmpreparaty
Jubilant HollisterStier
Juniper Pharmaceuticals
JunoPacific
K C Pharmaceutical
Kamat Pharmatech
Katsura Chemical
Kaysersberg Pharmaceuticals
Kemwell
Keshava Organics
Kilitch Drugs
Korten
KP Pharmaceutical Technology
Krishlar Pharma
Kyowa Pharma Chemical
Labiana Group
Laboratoires Thea
Laboratorios Entema
Laboratorios Grin
Laboratorios Lesvi
Laboratorios Sophia
Lacrivera
Laurus Synthesis
Lawson Health Research Institute
Lenus LifeCare
Lifekyor Pharmaceuticals
Lifezen Healthcare
Lighthouse Imaging
LOBA Feinchemie
Logos Pharma
Lohmann
Lomapharm
Lubrizol
Maastricht University Medical Center
MacFarlan Smith
Macter International
Mahidol University
Makcur Laboratories
Martin & Brown Biosciences
Massachusetts Eye and Ear Infirmary
Massachusetts General Hospital
Maxnova Healthcare
Maya Biotech
Mayo Clinic
MD Anderson Cancer Center
Medbio
MEDFE INDIA
Medical University of South Carolina
Medical University of Vienna
Medichem
Medisearch Laboratories
Medpharm
Memorial Sloan Kettering Cancer Center
Mercator Pharmaceutical Solutions
Merck
Micro Labs
Mission Laboratories
MMG Healthcare
Modern Medical Equipment
Moorfields Eye Hospital
Morgen Helathcare
Mylan
Nakoda Chemicals
National Cancer Institute
National Eye Institute
National Heart, Lung, and Blood Institute
National Institute of Allergy and Infectious Diseases
National Institute of Child Health and Human Development
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
National Institute on Aging
National Institutes of Health
National Institutes of Health Clinical Center
National Taiwan University Hospital
Neiss Labs
Nemera
NEO Tech Medical
Neuland Laboratories
NewGen BioPharma
Nextar Chempharma Solutions
NextPharma
Nimbles Biotech
Nitin Lifesciences
Nitto Medic
Nivon Specialities
Northwestern University
Novartis
Nutragen Pharma
Nvron Life Science
NYU Langone Health
Oceanic Pharmachem
Ohio State University
Olamic Pharma
Olon
Ora
Oregon Health and Science University
PannonPharma
Park Pharmaceuticals
Patheon
Perrigo
Pfizer
Pfizer CentreOne
Pharma Stulln
Pharmaloop
Pharmapack
PHARMA-Q
Pharmascience
Pharmer
Phillips-Medisize
Phoenix DeVentures
Phytex Australia
Pillar5 Pharma
Piramal Pharma Solutions
PMC SMART Solutions
Polpharma
Polyzen
PrimaPharma
Prisha Healthcare
Procos
Product Resources
ProMed Pharma
Proton Pharma
Pushkar Pharma
Qilu Pharmaceutical
Qualiphar-Gifrer
Qualitron Bio Medica
Quality Tech Services
Qualtra Pharmaceuticals
Radico Remedies
RAFARM
Recipharm
Red Star Contract Manufacturing
REDWING Pharma
Regeneron Pharmaceuticals
Remington Pharmaceuticals
Ritedose
Riverside Medical Packaging
Roche
Rchling Medical
Rohto Pharmaceuticals
Rompharm
Rubicon Research
Rusan Pharma
Salvat
Salvus Pharma
Samsung Medical Center
Sanbio
SANOCHEMIA Pharmazeutika
Sanofi
Santen
Saphnix Lifesciences
Saraca Solutions
Sarvodaya Drugs & Pharmaceuticals
SCD Pharmaceuticals
ScinoPharm Taiwan
Second Source Medical
Selvok Pharmaceutical
Sensimed
Sentiss Pharma
Seoul National University Hospital
Shahid Beheshti University of Medical Sciences
Shandong Xinhua Pharmaceutical
Sheba Medical Center
Shenzhen Haorui Industrial
Shilpa Medicare
Shire
SHL Group
Siegfried
Singapore National Eye Centre
Sinphar Pharmaceutical
Sion Healthcare
Smruthi Organics
Societa Italiana Medicinali Scandicci
Sofarimex
Softigel
Solitaire Pharmacia
SOVEREIGN PHARMA
Sovrin Plastics
Spark Therapeutics
Sparton
Spectrum Plastics Group
Square Pharmaceuticals
Sricure Herbs
SRS Pharmaceutical
Stanford University
StarFish Medical
Stellartech
Sterling Pharmaceutical Services
Stevanato Group
Strategix Medical Solutions
Sun Yat-sen University
Sungwoo Life Sciences
Sunways
Swiss Pharma
Symed Labs
Syncom Healthcare
Systochem Laboratories
Tahira Industries
Taj Pharmaceuticals
Takeda
Tara Innovations
Tegra Medical
Teika Pharmaceutical
Teligent
Texas Therapeutics
The Cleveland Clinic
The Hong Kong Polytechnic University
Titan Pharma
Tonus-Les
Torrent Pharmaceuticals
Trelleborg Sealing Solutions
Trumac Healthcare
Unichem Laboratories
Uni-Med India
Union Quimico Farmacutica
Unison Pharmaceuticals
University Health Network, Toronto
University Hospital Center of Bordeaux
University of Alabama at Birmingham
University of British Columbia
University of California, Davis
University of California, Los Angeles
University of California, San Diego
University of California, San Francisco
University of Chicago
University of Colorado, Denver
University of Iowa
University of Miami
University of Michigan
University of North Carolina, Chapel Hill
University of Oxford
University of Pittsburgh
University of Rochester
University of So Paulo
University of Utah
University of Waterloo
University of Wisconsin, Madison
University of Zurich
URSAPHARM Arzneimittel
USV
Valentis Pharma
Valtronic
VDASP Pharmaceuticals
Vergo Pharma Research Laboratories
VersaPharm
Vetter Pharma
Viant Medical
Vibcare
Vienna Institute for Research in Ocular Surgery
Vivimed
VxP Pharma
Wanbury
Wannock pharmaceuticals
Washington University School of Medicine
Wenzhou Medical University
Wills Eye Hospital
Wintac
Wockhardt
Wuhu Sanyi Xincheng Pharmaceutical
WuXi AppTec
Xellia Pharmaceuticals
Y S Lab
Yale University
YaoPharma
Yonsei University
Zenius
Zenlabs
Zylig Lifesciences

For more information about this report visit https://www.researchandmarkets.com/r/jo9hbh

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets